EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.62
-0.23 (-8.07%)
▼
5d:
-15.76%
30d:
-21.79%
90d:
+48.86%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
EDIT is down 15.8% this week, but smart money is accumulating calls. Top strike: $2.5 2026-06-18 with 155 OI. Call ratio: 83% View Scanner →
Strength: 10.0/10
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EDIT is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EDIT is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.62, which is considered oversold relative to its 30-day fair value range of $2.81 to $3.29.
Technical Outlook: Technically, EDIT is showing support break momentum. The price is currently testing key support at $2.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.78 (+120.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDIT is showing support break momentum. The price is currently testing key support at $2.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.78 (+120.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.81 -
$3.29
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 120.5% below Wall St target ($5.78)
- WARNING: Recommendation downgraded due to -15.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.81 -
$3.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.69
Resistance Level
$3.27
Current Trend
Support Break
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.89
Wall Street Target
$5.78
(+120.5%)
Revenue Growth (YoY)
-39.2%
Profit Margin
-281.6%
Share & Embed Analysis
Last updated: May 16, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison
SELL
474 shares
2026-03-03
Gilmore Neil O'neill
SELL
5394 shares
2026-03-03
Linda Burkly
SELL
749 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
